Regeneron Pharmaceuticals REGN Product And Service Other — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's product and service other — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's product and service other — revenue?
- Regeneron Pharmaceuticals (REGN) reported product and service other — revenue of $171.2M in Q1 2026.
- How has Regeneron Pharmaceuticals's product and service other — revenue changed year-over-year?
- Regeneron Pharmaceuticals's product and service other — revenue increased by 109.0% year-over-year, from $81.9M to $171.2M.
- What is the long-term trend for Regeneron Pharmaceuticals's product and service other — revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's product and service other — revenue has grown at a 25.7% compound annual growth rate (CAGR), from $281.2M to $702.6M.
- What does product and service other — revenue mean?
- This metric represents revenue streams generated by the company that fall outside of its primary core product franchises or major therapeutic segments. It typically includes income from collaboration agreements, milestone payments, royalties, and contract manufacturing services provided to third parties. These revenues are often non-recurring or tied to specific partnership milestones rather than direct product sales.